Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy

Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In the last decades, lipid-based nanoparticles-solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, and lipid-polymer hybrid nanoparticles-have received particular interest in antica...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-01, Vol.15 (1), p.216
Main Authors: Marques, Ana Camila, Costa, Paulo C, Velho, Sérgia, Amaral, Maria Helena
Format: Article
Language:English
Subjects:
active targeting
Adsorption
Antibodies
Antigens
cancer
Cancer therapies
Drug delivery systems
functionalization
Immunoglobulins
Ligands
lipid nanoparticles
Lipids
Nanoparticles
Polyethylene glycol
Review
SLN
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c505t-4a192384734dbfc948af48442160d11bfdd06031d55d1a9dfd89b89571b4ad53
cites cdi_FETCH-LOGICAL-c505t-4a192384734dbfc948af48442160d11bfdd06031d55d1a9dfd89b89571b4ad53
container_end_page
container_issue 1
container_start_page 216
container_title Pharmaceutics
container_volume 15
creator Marques, Ana Camila
Costa, Paulo C
Velho, Sérgia
Amaral, Maria Helena
description Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In the last decades, lipid-based nanoparticles-solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, and lipid-polymer hybrid nanoparticles-have received particular interest in anticancer drug delivery to solid tumors. To improve selectivity for target cells and, thus, therapeutic efficacy, lipid nanoparticles have been functionalized with antibodies that bind to receptors overexpressed in angiogenic endothelial cells or cancer cells. Most papers dealing with the preclinical results of antibody-conjugated nanoparticles claim low systemic toxicity and effective tumor inhibition, which have not been successfully translated into clinical use yet. This review aims to summarize the current "state-of-the-art" in anticancer drug delivery using antibody-functionalized lipid-based nanoparticles. It includes an update on promising candidates that entered clinical trials and some explanations for low translation success.
doi_str_mv 10.3390/pharmaceutics15010216
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c74f0eacbc6747d89b144461c878c686</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c74f0eacbc6747d89b144461c878c686</doaj_id><sourcerecordid>2768224729</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-4a192384734dbfc948af48442160d11bfdd06031d55d1a9dfd89b89571b4ad53</originalsourceid><addsrcrecordid>eNptkUtvEzEUhS0EolXpTwCNxIZNqB_Xrw1SVSitFJVN9pbH9iSOJuPBnqEqvx43CVWL8MaPe-6ne3wQek_wZ8Y0vhg3Nu-sC_MUXSEcE0yJeIVOidZ6AZqy18_OJ-i8lC2uizGimH6LTpgQUingp-huGcfomzs7pNHmiutDaa7nwU0xDbaPv4Nv7uO0aS6HKbbJx1ruUt5fnR1cyM3XPK-b1SZkOz68Q28625dwftzP0Or62-rqZrH88f326nK5cBzzaQGW1MEUSAa-7ZwGZTtQANUF9oS0nfdYYEY8555Y7TuvdKs0l6QF6zk7Q7cHrE92a8YcdzY_mGSj2T-kvDZHM8ZJ6HCwrnVCgnzkEAAQxCmpnFCisr4cWOPc7oJ3YZiy7V9AX1aGuDHr9MtoJUADrYBPR0BOP-dQJrOLxYW-t0NIczFUCkUpSKqr9OM_0m2ac_3nvUpSwRnFVcUPKpdTKTl0T8MQbB7zN__Nv_Z9eO7kqetv2uwPN66v3A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2767265320</pqid></control><display><type>article</type><title>Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy</title><source>PubMed Central Free</source><source>Publicly Available Content Database</source><creator>Marques, Ana Camila ; Costa, Paulo C ; Velho, Sérgia ; Amaral, Maria Helena</creator><creatorcontrib>Marques, Ana Camila ; Costa, Paulo C ; Velho, Sérgia ; Amaral, Maria Helena</creatorcontrib><description>Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In the last decades, lipid-based nanoparticles-solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, and lipid-polymer hybrid nanoparticles-have received particular interest in anticancer drug delivery to solid tumors. To improve selectivity for target cells and, thus, therapeutic efficacy, lipid nanoparticles have been functionalized with antibodies that bind to receptors overexpressed in angiogenic endothelial cells or cancer cells. Most papers dealing with the preclinical results of antibody-conjugated nanoparticles claim low systemic toxicity and effective tumor inhibition, which have not been successfully translated into clinical use yet. This review aims to summarize the current "state-of-the-art" in anticancer drug delivery using antibody-functionalized lipid-based nanoparticles. It includes an update on promising candidates that entered clinical trials and some explanations for low translation success.</description><identifier>ISSN: 1999-4923</identifier><identifier>EISSN: 1999-4923</identifier><identifier>DOI: 10.3390/pharmaceutics15010216</identifier><identifier>PMID: 36678845</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>active targeting ; Adsorption ; Antibodies ; Antigens ; cancer ; Cancer therapies ; Drug delivery systems ; functionalization ; Immunoglobulins ; Ligands ; lipid nanoparticles ; Lipids ; Nanoparticles ; Polyethylene glycol ; Review ; SLN</subject><ispartof>Pharmaceutics, 2023-01, Vol.15 (1), p.216</ispartof><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-4a192384734dbfc948af48442160d11bfdd06031d55d1a9dfd89b89571b4ad53</citedby><cites>FETCH-LOGICAL-c505t-4a192384734dbfc948af48442160d11bfdd06031d55d1a9dfd89b89571b4ad53</cites><orcidid>0000-0002-1152-3398 ; 0000-0003-1247-6738 ; 0000-0002-3209-3366</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2767265320/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2767265320?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36678845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marques, Ana Camila</creatorcontrib><creatorcontrib>Costa, Paulo C</creatorcontrib><creatorcontrib>Velho, Sérgia</creatorcontrib><creatorcontrib>Amaral, Maria Helena</creatorcontrib><title>Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy</title><title>Pharmaceutics</title><addtitle>Pharmaceutics</addtitle><description>Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In the last decades, lipid-based nanoparticles-solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, and lipid-polymer hybrid nanoparticles-have received particular interest in anticancer drug delivery to solid tumors. To improve selectivity for target cells and, thus, therapeutic efficacy, lipid nanoparticles have been functionalized with antibodies that bind to receptors overexpressed in angiogenic endothelial cells or cancer cells. Most papers dealing with the preclinical results of antibody-conjugated nanoparticles claim low systemic toxicity and effective tumor inhibition, which have not been successfully translated into clinical use yet. This review aims to summarize the current "state-of-the-art" in anticancer drug delivery using antibody-functionalized lipid-based nanoparticles. It includes an update on promising candidates that entered clinical trials and some explanations for low translation success.</description><subject>active targeting</subject><subject>Adsorption</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>cancer</subject><subject>Cancer therapies</subject><subject>Drug delivery systems</subject><subject>functionalization</subject><subject>Immunoglobulins</subject><subject>Ligands</subject><subject>lipid nanoparticles</subject><subject>Lipids</subject><subject>Nanoparticles</subject><subject>Polyethylene glycol</subject><subject>Review</subject><subject>SLN</subject><issn>1999-4923</issn><issn>1999-4923</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkUtvEzEUhS0EolXpTwCNxIZNqB_Xrw1SVSitFJVN9pbH9iSOJuPBnqEqvx43CVWL8MaPe-6ne3wQek_wZ8Y0vhg3Nu-sC_MUXSEcE0yJeIVOidZ6AZqy18_OJ-i8lC2uizGimH6LTpgQUingp-huGcfomzs7pNHmiutDaa7nwU0xDbaPv4Nv7uO0aS6HKbbJx1ruUt5fnR1cyM3XPK-b1SZkOz68Q28625dwftzP0Or62-rqZrH88f326nK5cBzzaQGW1MEUSAa-7ZwGZTtQANUF9oS0nfdYYEY8555Y7TuvdKs0l6QF6zk7Q7cHrE92a8YcdzY_mGSj2T-kvDZHM8ZJ6HCwrnVCgnzkEAAQxCmpnFCisr4cWOPc7oJ3YZiy7V9AX1aGuDHr9MtoJUADrYBPR0BOP-dQJrOLxYW-t0NIczFUCkUpSKqr9OM_0m2ac_3nvUpSwRnFVcUPKpdTKTl0T8MQbB7zN__Nv_Z9eO7kqetv2uwPN66v3A</recordid><startdate>20230108</startdate><enddate>20230108</enddate><creator>Marques, Ana Camila</creator><creator>Costa, Paulo C</creator><creator>Velho, Sérgia</creator><creator>Amaral, Maria Helena</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1152-3398</orcidid><orcidid>https://orcid.org/0000-0003-1247-6738</orcidid><orcidid>https://orcid.org/0000-0002-3209-3366</orcidid></search><sort><creationdate>20230108</creationdate><title>Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy</title><author>Marques, Ana Camila ; Costa, Paulo C ; Velho, Sérgia ; Amaral, Maria Helena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-4a192384734dbfc948af48442160d11bfdd06031d55d1a9dfd89b89571b4ad53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>active targeting</topic><topic>Adsorption</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>cancer</topic><topic>Cancer therapies</topic><topic>Drug delivery systems</topic><topic>functionalization</topic><topic>Immunoglobulins</topic><topic>Ligands</topic><topic>lipid nanoparticles</topic><topic>Lipids</topic><topic>Nanoparticles</topic><topic>Polyethylene glycol</topic><topic>Review</topic><topic>SLN</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marques, Ana Camila</creatorcontrib><creatorcontrib>Costa, Paulo C</creatorcontrib><creatorcontrib>Velho, Sérgia</creatorcontrib><creatorcontrib>Amaral, Maria Helena</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marques, Ana Camila</au><au>Costa, Paulo C</au><au>Velho, Sérgia</au><au>Amaral, Maria Helena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy</atitle><jtitle>Pharmaceutics</jtitle><addtitle>Pharmaceutics</addtitle><date>2023-01-08</date><risdate>2023</risdate><volume>15</volume><issue>1</issue><spage>216</spage><pages>216-</pages><issn>1999-4923</issn><eissn>1999-4923</eissn><abstract>Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In the last decades, lipid-based nanoparticles-solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, and lipid-polymer hybrid nanoparticles-have received particular interest in anticancer drug delivery to solid tumors. To improve selectivity for target cells and, thus, therapeutic efficacy, lipid nanoparticles have been functionalized with antibodies that bind to receptors overexpressed in angiogenic endothelial cells or cancer cells. Most papers dealing with the preclinical results of antibody-conjugated nanoparticles claim low systemic toxicity and effective tumor inhibition, which have not been successfully translated into clinical use yet. This review aims to summarize the current "state-of-the-art" in anticancer drug delivery using antibody-functionalized lipid-based nanoparticles. It includes an update on promising candidates that entered clinical trials and some explanations for low translation success.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36678845</pmid><doi>10.3390/pharmaceutics15010216</doi><orcidid>https://orcid.org/0000-0002-1152-3398</orcidid><orcidid>https://orcid.org/0000-0003-1247-6738</orcidid><orcidid>https://orcid.org/0000-0002-3209-3366</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1999-4923
ispartof Pharmaceutics, 2023-01, Vol.15 (1), p.216
issn 1999-4923
1999-4923
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c74f0eacbc6747d89b144461c878c686
source PubMed Central Free; Publicly Available Content Database
subjects active targeting
Adsorption
Antibodies
Antigens
cancer
Cancer therapies
Drug delivery systems
functionalization
Immunoglobulins
Ligands
lipid nanoparticles
Lipids
Nanoparticles
Polyethylene glycol
Review
SLN
title Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T20%3A15%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20Nanoparticles%20Functionalized%20with%20Antibodies%20for%20Anticancer%20Drug%20Therapy&rft.jtitle=Pharmaceutics&rft.au=Marques,%20Ana%20Camila&rft.date=2023-01-08&rft.volume=15&rft.issue=1&rft.spage=216&rft.pages=216-&rft.issn=1999-4923&rft.eissn=1999-4923&rft_id=info:doi/10.3390/pharmaceutics15010216&rft_dat=%3Cproquest_doaj_%3E2768224729%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c505t-4a192384734dbfc948af48442160d11bfdd06031d55d1a9dfd89b89571b4ad53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2767265320&rft_id=info:pmid/36678845&rfr_iscdi=true